Setmelanotide

The leptin-melanocortin pathway runs from leptin to POMC neurons to alpha-MSH to MC4R, and mutations anywhere upstream - POMC, PCSK1, LEPR - leave MC4R itself intact but unstimulated. Setmelanotide is a cyclic octapeptide that agonises MC4R directly, bypassing the broken segment and restoring satiety and energy expenditure signalling. In these rare genotypes and in Bardet-Biedl syndrome the effect is dramatic, with large BMI reductions and profound reductions in hyperphagia. In acquired hypothalamic obesity, where hypothalamic injury from a tumour or its treatment disrupts the same pathway, the TRANSCEND trial showed an 18.4% placebo-adjusted BMI reduction. In common polygenic obesity, MC4R agonism adds little.

Targets: MC4 receptor, MC1 receptor (secondary)

• · Adults start at 2 mg daily for two weeks; if tolerated the dose increases to 3 mg daily, and if not tolerated it drops to 1.5 mg.
• · Weight-banded starting doses of 1 mg or 1.5 mg with titration to a maximum of 2.5 or 3 mg depending on age and weight.

Work out your exact syringe units →

• very commonSkin hyperpigmentation and darkening of naevi— MC1R cross-activity; reversible on stopping but requires a skin exam before and during treatment.
• very commonInjection-site reaction— Daily injections.
• very commonNausea
• commonSpontaneous penile erections— Melanocortin class effect, the same pharmacology PT-141 is sold for.
• uncommonDepression and suicidal ideation— A labelled warning; monitor mood, particularly in adolescents.

• Pregnancy.
• Pre-existing depression or suicidal ideation without close psychiatric monitoring.
• Personal or family history of melanoma - a full skin examination is required before starting and periodically thereafter.
• Obesity not caused by an established MC4R-pathway defect - it simply will not work.

• redundantmelanotan-ii — Both are melanocortin agonists; MT-II is non-selective and unapproved.
• redundantpt-141 — Overlapping MC4R agonism; combining amplifies erectile and nausea effects.
• synergysemaglutide — Different pathways, occasionally combined in hypothalamic obesity, though evidence is limited.

• · Full skin examination before starting and periodically during treatment.
• · Mood and suicidality, especially in adolescents.
• · BMI and hyperphagia questionnaires.
• · Growth in paediatric patients.

FDA- and EMA-approved as Imcivree for specific rare obesity syndromes; prescribing is restricted and genotype confirmation is normally required.

• Clement et al. 2020, setmelanotide in POMC and LEPR deficiency, Lancet Diabetes & Endocrinology (trial)
• Haqq et al. 2022, setmelanotide in Bardet-Biedl syndrome, Lancet Diabetes & Endocrinology (trial)
• Rhythm Pharmaceuticals 2026, TRANSCEND phase 3 in acquired hypothalamic obesity (trial)
• Imcivree US prescribing information (label)

Setmelanotide is the only drug here that acts downstream of the leptin-melanocortin pathway rather than on gut hormones, and it is the clearest example in obesity medicine of a drug that works spectacularly in the right genotype and barely at all outside it. The pathway runs: leptin from adipose tissue signals energy sufficiency to arcuate POMC neurons, POMC is cleaved by PCSK1 into alpha-MSH, alpha-MSH activates MC4 receptors on paraventricular neurons, and MC4R signalling suppresses hunger and raises energy expenditure. Mutations anywhere upstream - in POMC, in PCSK1, in the leptin receptor - break the signal, and the result is profound, unrelenting hyperphagia from early childhood. Setmelanotide replaces the missing alpha-MSH signal by directly agonising MC4R, restoring a pathway that was severed rather than adding a new pressure on top of an intact one. That is why the effect size in the right patients is extraordinary and why it does very little in ordinary polygenic obesity where the pathway is working fine. The March 2026 extension to acquired hypothalamic obesity - obesity after damage to the hypothalamus from a craniopharyngioma or its treatment - follows the same logic: the arcuate signal is destroyed anatomically rather than genetically, and restoring MC4R agonism downstream bypasses the damage. The distinctive side effects come from melanocortin receptor cross-talk: skin hyperpigmentation from MC1R activation, which is expected and reversible, and spontaneous penile erections in males from central melanocortin signalling. Prescribing normally requires genotype confirmation, which is the correct gate.

The dominant failure is using it in the wrong person. In unselected polygenic obesity the effect is small, and the cost is enormous. The label's 12-16 week stopping rule exists for exactly that reason and should be honoured. The second issue is the hyperpigmentation: it is expected, dose-related and reversible, but it darkens existing moles, and without a documented baseline skin examination it becomes impossible to distinguish a drug effect from a changing melanocytic lesion. Third, spontaneous penile erections occur in a meaningful proportion of male patients and people are not usually warned. Fourth, depression has been reported and needs asking about rather than waiting for.

• Melanocortin-4 receptor (MC4R) — Potent agonist; specific affinity not verified in this session

  Restores the satiety signal downstream of a broken leptin-melanocortin pathway. Reduces hyperphagia dramatically in POMC, PCSK1 and LEPR deficiency, in Bardet-Biedl and Alstrom syndromes and in acquired hypothalamic obesity.

• Melanocortin-1 receptor (MC1R) — Cross-reactive

  Skin and hair darkening. Expected, dose-related and reversible on discontinuation - but people should be told to expect it rather than discovering it.

• Melanocortin-3 receptor (MC3R) — Cross-reactive

  Contributes to energy homeostasis; the clinical significance in humans is not well defined.

• Setmelanotide phase 3 in POMC and LEPR deficiency obesity Phase 3 · n=21 · 52 weeks · 2020

  Proportion achieving at least 10% weight reduction at approximately one year in severe obesity due to POMC or LEPR deficiency - 80% of the POMC cohort and 45% of the LEPR cohort.

• Setmelanotide phase 3 in Bardet-Biedl and Alstrom syndromes Phase 3 · n=32 · 52 weeks · 2022

  Reduction in BMI and in hunger scores in Bardet-Biedl syndrome, supporting the 2022 indication extension.

• TRANSCEND Phase 3 · 52 weeks · 2026

  Setmelanotide for acquired hypothalamic obesity, reported as an approximately 18.4% placebo-adjusted BMI reduction; supported the March 2026 indication extension.

Hunger reduction is often reported within the first one to two weeks and is described by patients and families as the most striking part - the change in hyperphagia frequently precedes any change on the scale. Steady state in about three days. BMI change assessed at 12-16 weeks for the stopping rule, and at 52 weeks for the registration endpoints.

Setmelanotide acts on a completely different pathway from every incretin, so combining it with a GLP-1 agonist is mechanistically non-redundant and is done clinically in hypothalamic obesity where a single agent is often insufficient. There is limited formal trial evidence for the combination. The important framing is that setmelanotide is not a general-purpose weight drug you add to a stack - it is a replacement therapy for a specific broken signalling pathway, and outside that context it does very little regardless of what it is combined with. Sun protection is a genuine adjunct here rather than a throwaway: MC1R activation darkens skin and people should not read that as photoprotection.

Against every incretin: not comparable, and the comparison misleads. Setmelanotide restores a broken pathway in a defined population; GLP-1 agonists add a satiety signal on top of an intact one in the general population. In genotype-positive patients setmelanotide does what no GLP-1 agonist can; in everyone else the reverse is true. Against other melanocortin agonists such as bremelanotide and afamelanotide: same receptor family, entirely different indications and receptor selectivity.

An orphan drug for rare genetic disease, priced accordingly - annual costs are commonly reported in the high five to six figures in the US. No verified figure is given here rather than guessing. Access is normally through specialist centres and payer authorisation, not retail purchase.

• ?The dosing and titration schedule from section 2 of the label was not verified in this session, so no titration ladder is given.
• ?Absolute bioavailability is not stated in the label.
• ?The amino acid sequence is not enumerated in the label text and no sequence string is given rather than reconstructing one.
• ?Receptor binding affinities at MC1R, MC3R and MC4R were not verified.
• ?Participant numbers for the 2020 and 2022 phase 3 trials are as commonly reported and were not individually re-verified against the papers.
• ?The TRANSCEND 18.4% placebo-adjusted figure is as reported in the Core record and was not extracted from the paper in this session.
• ?Pricing was not verified.

• Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Clement K et al., Lancet Diabetes Endocrinol, 2020 · PMID 33137293

  The original registration trials. Small numbers, enormous effect sizes - the opposite shape from every other trial in this class.

• Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period Haqq AM et al., Lancet Diabetes Endocrinol, 2022 · PMID 36356613

  The Bardet-Biedl indication extension.

• Setmelanotide for the Treatment of Acquired Hypothalamic Obesity Miller JL et al., N Engl J Med, 2026 · PMID 42418774

  TRANSCEND, the acquired hypothalamic obesity trial behind the 2026 indication extension.

• IMCIVREE (setmelanotide) injection - US prescribing information, sections 11 and 12.3 Rhythm Pharmaceuticals, Inc, DailyMed

  Source for the 8-hour tmax, 75.2 L volume of distribution, 79.1% protein binding, 7.15 L/h clearance, 11-hour half-life and 39% unchanged urinary excretion.